Celgene

Many Drugmakers Ignore Trump—and Raise Prices Anyway
Many Drugmakers Ignore Trump—and Raise Prices Anyway
Bloomberg
drug pricing
Donald Trump
Pfizer
Celgene
Roche
Novo Nordisk
Flag link:
MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too
MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too
Fierce Pharma
patents
Novartis
MS
Gilenya
Celgene
exclusivity
Flag link:
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Fierce Biotech
Celgene
clinical trials
bb2121
Bluebird Bio
Multiple Myeloma
CAR-T
Flag link:
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
Fierce Pharma
Pfizer
Celgene
drug pricing
Donald Trump
Revlimid
Pomalyst
Flag link:
A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept
A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept
Endpoints
Celgene
Acceleron
beta thalassemia
luspatercept
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:
3 Best Biotech Acquisitions of 2018 (So Far)
3 Best Biotech Acquisitions of 2018 (So Far)
Motley Fool
M&A
biotech
Celgene
Juno Therapeutics
Novartis
AveXis
Roche
Foundation Medicine
Flag link:
Celgene pledges to limit price hikes—or does it?
Celgene pledges to limit price hikes—or does it?
Fierce Pharma
Allergan
Sanofi
Celgene
drug pricing
Flag link:
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Endpoints
Roche
Tecentriq
Genentech
triple negative breast cancer
Celgene
Abraxane
Flag link:
Pharma's 2 Biggest Setbacks in 2018
Pharma's 2 Biggest Setbacks in 2018
Motley Fool
AbbVie
Celgene
Rova-T
ozanimod
Flag link:
Acceleron blood disease drug hits goal in pivotal clinical trial
Acceleron blood disease drug hits goal in pivotal clinical trial
Stat
Acceleron
Celgene
luspatercept
clinical trials
myelodysplastic syndrome
Flag link:
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Yahoo/Benzinga
Bluebird Bio
Celgene
LentiGlobin
Madrigal Pharmaceuticals
Flag link:
Why Impact Biomedicines Could Be Celgene’s Next Embarrassment
Why Impact Biomedicines Could Be Celgene’s Next Embarrassment
NY Shock Exchange
Celgene
Impact Biomedicines
Flag link:
Celgene executive blames Receptos for ozanimod filing fail
Celgene executive blames Receptos for ozanimod filing fail
Fierce Biotech
Celgene
Receptos
ozanimod
Flag link:
Big News Is Fast Approaching for Celgene
Big News Is Fast Approaching for Celgene
Motley Fool
Celgene
luspatercept
beta thalassemia
MDS
Flag link:
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
Flag link:
ASCO18: Who were the big winners and losers?
ASCO18: Who were the big winners and losers?
Biopharma Dive
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Flag link:
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
Biopharma Dive
Celgene
JCAR017
liso-cel
CAR-T
B-cell non-Hodgkin lymphoma
ASCO 2018
Flag link:
#ASCO18: A Weekend of Surprises
#ASCO18: A Weekend of Surprises
Motley Fool
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Flag link:
5 Best-Selling Orphan Drugs in the U.S.
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Flag link:

Pages